
    
      This is a multicenter, open-label extension study designed to assess the long-term safety of
      evolocumab in subjects who completed the FOURIER study,which is a randomized
      placebo-controlled study of evolocumab in subjects with clinically evident atherosclerotic
      CVD on stable effective statin therapy. Eligible subjects at sites participating in FOURIER
      OLE who have signed the FOURIER OLE informed consent may be enrolled at the completion of
      FOURIER study.
    
  